Dual-Directional Immunomodulatory Effects of Corbrin Capsule on Autoimmune Thyroid Diseases
Table 3
Baseline and end of treatment of subjects in Graves’ disease.
GD-Tx
GD-Ct
Baseline
End of treatment
value
Baseline
End of treatment
value
FT3 (pmol/L)
9.52 7.53
5.02 3.55
0.098
8.96 1.43
6.10 1.18
0.077
FT4 (pmol/L)
23.01 17.26
14.90 2.13
0.130
25.93 10.46
18.52 2.73
0.340
TSH (IU/L)
0.07 0.13
1.34 1.16
0.042
0.09 0.17
1.14 1.07
<0.001
TPO-Ab (IU/mL)
659.28 585.85
434.99 229.93
0.012
672.39 463.51
575.64 361.87
0.313
TR-Ab (IU/mL)
34.51 17.97
11.57 4.07
<0.001
31.16 11.46
27.07 8.14
0.083
CD3+ (%)
66.98 9.40
66.31 9.70
0.462
67.62 8.36
66.98 5.31
0.761
CD4+ (%)
38.30 5.37
34.86 2.03
0.044
36.96 2.29
36.88 3.46
0.947
CD8+ (%)
21.93 4.46
24.89 3.29
0.047
21.98 6.56
23.84 5.12
0.150
CD4/CD8 ratio
1.86 0.66
1.42 0.19
0.022
1.89 0.79
1.60 0.43
0.209
The data of GD-Tx group and GD-Ct group were compared between the start and end of treatment (24 weeks). In the GD-Tx groups, there were a significant decrease of CD4+, an increase of CD8+, and a decreased CD4/CD8 ratio compared to the baseline. None of the parameters changed significantly in GD-Ct group.
